Tailwinds' Take: while this news comes suddenly and will likely cause some selling in the stock, we view it as constructive. Mark Day has never gotten the traction needed with financing and, frankly, our communications with him have been...
Tailwinds' Take: having emerged from their silent period, Bioasis appears to be very excited about the data they are generating as they start opening their kimono to investors. Needing money soon, my belief is they have a...
I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a swoon. This time, thanks to the ratcheting up of trade tension, we looked ready for...
When I removed Bioasis from the Tailwinds Select Portfolio, it was with great reluctance. This is a Company that I believe has groundbreaking, lifesaving, technology. The management team is strong and the board is outstanding. All the pieces were...
October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from several disastrous meltdowns. These include Black Monday in 1987 when the market lost 23% in...
Every year for the past 36 years, Byron Wien has put out a list of “Top 10 Surprises” for the coming year. The list is comprised of potential macroeconomic events that have, according to Mr. Wien,...
Tailwinds' Take: Bioasis appears to have done the necessary pre-clinical work to attract interest from partners. While still early stage, it's apparent that the platform has significant promise and I expect to see more deals in the near future. GUILFORD,...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system...
This week Bioasis heard back from the FDA on written questions they had submitted. These questions concern their lead investigational candidate xB3-001 and its development path. The Company’s goal, of course, is to bring this therapeutic into clinical development...
Tailwinds' Take: having a manufacturing partner is a key step towards clinical development of their drug candidates. With their recent financing, which we believe had large insider participation, behind them, we would expect to see more press releases out...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.